About this trial
Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory/airway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and/or monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.
For this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring/treatment (i.e., 2 L O2/min via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \<85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
undergoing an interventional (intent) ERCP procedure
18-99 years
Male or female
Nurse-administered sedation
Disqualifiers
History of allergic reaction to Propofol
Tracheostomy
Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge
Pregnant patients
Trial design
Parallel
Treatments tested in this trial
Nasal PAP Ventilation System
Devicemedical devices that provide nasal positive airway pressure ventilation during endoscopy
Low Flow Oxygen
Devicelow flow oxygen though nasal cannula
Capnometry
Devicecapnometry measurement
Treatment groups
Trial outcomes
Primary outcomes
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the standard management group
Secondary outcomes
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) across the three groups
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the capnometry group vs. the standard management group
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the capnometry group
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the PAP group vs. the control group
Sponsors and contacts
Click on the lead sponsor to view all of their trials.